Please assess the completion status of the following clinical trial:

Trial Title: Open Label Extension to Bridging Study CTBM100C2303

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed all visits in study CTBM100C2303, and visit 4 took place not more than 5 days before enrollment into this study.~* Confirmed diagnosis of cystic fibrosis participants with P. aeruginosa infection.~* Forced Expiratory Volume in One Second (FEV1) at screening (study CTBM100C2303) must be between 25% and 80% of normal predicted values.~Exclusion Criteria:~* Any use of inhaled anti-pseudomonal antibiotics between the termination of the core trial CTMB100C2303 and the enrollment into this study.~* Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Tobramycin Inhalation Powder (TIP) (Type: EXPERIMENTAL): Participants received 112 mg (four 28 mg capsules) of TIP administered by the T-326 Inhaler, twice a day (b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment (one cycle = 56 days) for up to 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).